Viridian Therapeutics, Inc. (VRDN) Technical Analysis & Indicators

Viridian Therapeutics, Inc. (VRDN) — Price $24.67 (closing price, October 30, 2026) — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Technical analysis of Viridian Therapeutics, Inc. (VRDN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED).

Price Performance

1 month+27.16%
3 months+27.76%
Year-to-date-20.73%
1 year+4.40%
3 years+75.21%
5 years+40.81%
10 years-63.45%

52-Week Range

52-week High$34.29
52-week Low$13.18
Avg Volume (90d)1.9M

Technical Indicators

SMA 50$21.66
SMA 200$21.76
Beta1.17
30-day Volatility (annualised)56.0%
Price vs SMA 50+13.9%
Price vs SMA 200+13.4%

Monthly Close (12 months)

MonthCloseChange
2025-12$31.12
2026-01$33.00+6.0%
2026-02$29.38-11.0%
2026-03$19.56-33.4%
2026-04$13.48-31.1%
2026-05$17.62+30.7%
2026-06$18.37+4.3%
2026-07$18.92+3.0%
2026-08$23.16+22.4%
2026-09$20.59-11.1%
2026-10$24.67+19.8%

Upcoming Earnings

DateEPS Est.Revenue Est.
2026-11-04$-1.02$5M
2026-08-06$-1.03
2026-05-05$-1.06
2026-02-26$-0.90$18M
2025-11-05$-0.82$16M
2025-08-06$-1.00
2025-05-06$-0.95

Price

Price$24.67 (closing price, October 30, 2026)
Market Cap$2.8B
ExchangeNASDAQ
CountryUS

Valuation Ratios

Price / Book4.02
EV / EBITDA-7.82
Dividend Yield0.00%

Financial Health

Debt / Equity0.37
Current Ratio16.95
Piotroski F-Score2
Altman Z-Score6.69

Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD

Explore sector: Healthcare · Biotechnology

More sections of VRDN: Overview · Financials · Valuation · Statistics · Estimates · Ownership · News · Events

Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks